<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02128321</url>
  </required_header>
  <id_info>
    <org_study_id>9766-CL-0053</org_study_id>
    <nct_id>NCT02128321</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine</brief_title>
  <official_title>A Phase 1 Open Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Basilea Pharmaceutica International Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of multiple doses of isavuconazole on the
      pharmacokinetics of Repaglinide and possible metabolites after single dose administration. In
      addition, this study will assess the effect of multiple doses of isavuconazole on the
      pharmacokinetics of caffeine and possible metabolites after single dose administration.
      Safety and tolerability of isavuconazole alone and in combination with Repaglinide or in
      combination with caffeine will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma repaglinide and possible metabolite concentration: Area under the concentration-time curve from time of dosing to the last quantifiable concentration (AUClast)</measure>
    <time_frame>Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma repaglinide and possible metabolite concentration: Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf)</measure>
    <time_frame>Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma repaglinide and possible metabolite concentration: Maximum concentration (Cmax)</measure>
    <time_frame>Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of caffeine and possible metabolite concentration: Area under the concentration-time curve from time of dosing to the last quantifiable concentration (AUClast)</measure>
    <time_frame>Days 3 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of caffeine and possible metabolite concentration: Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf)</measure>
    <time_frame>Days 3 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of caffeine and possible metabolite concentration: Maximum concentration (Cmax)</measure>
    <time_frame>Days 3 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma isavuconazole concentration: Trough concentration (Ctrough)</measure>
    <time_frame>Days 10-18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma isavuconazole concentration: Area under the concentration-time curve during the time interval between consecutive dosing (AUCtau)</measure>
    <time_frame>Days 13, 14 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma isavuconazole concentration: Maximum concentration (Cmax)</measure>
    <time_frame>Days 13, 14 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of plasma isavuconazole concentration: Time after dosing when Cmax occurs (tmax)</measure>
    <time_frame>Days 13, 14 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed through adverse events</measure>
    <time_frame>up to Day 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed through clinical laboratory evaluations</measure>
    <time_frame>up to Day 18</time_frame>
    <description>Laboratory assessments will include hematology, serum chemistry and urinalysis parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by 12-lead electrocardiograms (ECGs)</measure>
    <time_frame>up to Day 18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed through vital signs</measure>
    <time_frame>up to Day 18</time_frame>
    <description>Vital signs will be measured including oral temperature, pulse, and sitting blood pressure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pharmacokinetics of Repaglinide</condition>
  <condition>Pharmacokinetics of Caffeine</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Isavuconazole + Repaglinide + Caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isavuconazole three times a day on Days 5 and 6 and once a day on Days 7 through 17, repaglinide on Days 1 and Day 14, caffeine on Days 3 and 16</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isavuconazole</intervention_name>
    <description>oral</description>
    <arm_group_label>Isavuconazole + Repaglinide + Caffeine</arm_group_label>
    <other_name>BAL4815</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repaglinide</intervention_name>
    <description>oral</description>
    <arm_group_label>Isavuconazole + Repaglinide + Caffeine</arm_group_label>
    <other_name>PrandinÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>oral</description>
    <arm_group_label>Isavuconazole + Repaglinide + Caffeine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has a body weight of at least 50 kg and a body mass index of 18.5 to 32
             kg/m2, inclusive

          -  The subject's 12-lead electrocardiogram (ECG) is normal

          -  The subject's clinical laboratory test results are within normal limits

        Exclusion Criteria:

          -  The subject has any history or evidence of any clinically significant cardiovascular,
             gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic,
             urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major
             disease or malignancy

          -  Female subject has been pregnant within 6 months before screening or breast feeding
             within 3 months before screening

          -  The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac
             arrhythmia or torsade de pointes, structural heart disease, or family history of
             either Short or Long QT syndrome (suggested by sudden death of a close relative at a
             young age due to possible or probable cardiac causes). QT is the time between the
             start of the Q wave and the end of the T wave in the heart's electrical system

          -  The subject has/had febrile illness or symptomatic, viral, bacterial (including upper
             respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to
             clinic admission

          -  The subject has received a vaccination within the last 30 days prior to study drug
             administration

          -  The subject has a positive serology test for Hepatitis B surface antigen (HBsAg),
             Hepatitis A Immunoglobulin M antibody (anti HAV (IgM)), Hepatitis C antibody
             (anti-HCV), or human immunodeficiency virus (anti-HIV 1+2)

          -  The subject has a known or suspected allergy to any of the components of the trial
             products or the azole class of compounds, or a history of multiple and/or severe
             allergies to drugs or foods, or a history of severe anaphylactic reactions

          -  The subject has used tobacco or nicotine containing products in the last 6 months

          -  The subject has had treatment with any prescribed or non-prescribed drugs (including
             vitamins, natural and herbal remedies, e.g. St. John's wort) in the 2 weeks prior with
             the exception of hormonal methods of contraception, hormone replacement therapy, or
             occasional use of acetaminophen up to 2 g/day

          -  The subject has participated in any interventional clinical study or has received any
             investigational drugs within past 30 days or 5 half-lives, whichever is longer

          -  The subject has had any significant blood loss, donated one unit (450 mL) of blood or
             more, or received a transfusion of any blood or blood products within 60 days or
             donated plasma within 7 days prior to clinic admission

          -  The subject anticipates an inability to abstain from alcohol or caffeine use for 48
             hours prior and throughout the duration of the study; or from grapefruit, grapefruit
             juice, star fruit, or Seville oranges or any products containing these items from 72
             hours prior and throughout the duration of the study

          -  The subject has history of consuming more than 14 units of alcoholic beverages per
             week within 6 months prior to screening or has a history of alcoholism or
             drug/chemical/substance abuse within past 2 years prior to screening (Note: one unit =
             12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor) or the subject
             tests positive for alcohol or drugs of abuse (amphetamines, barbiturates,
             benzodiazepines, cannabinoids, cocaine, and opiates)

          -  The subject has taken part in strenuous exercise within 3 days before Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel Early Phase Clinical Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2014</study_first_submitted>
  <study_first_submitted_qc>April 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <last_update_submitted>April 29, 2014</last_update_submitted>
  <last_update_submitted_qc>April 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Isavuconazole</keyword>
  <keyword>Repaglinide</keyword>
  <keyword>Caffeine</keyword>
  <keyword>BAL4815</keyword>
  <keyword>BAL8728</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Repaglinide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

